All terms in BMONT

Label Id Description
copy number variant biomarker BMONT_0000005 [A biomarker of genomic variation in which blocks of DNA are missing or for which multiple copies exist.]
gait speed BMONT_0000127 [Gait speed, also known as walking speed, is a crucial parameter in the study of human locomotion and biomechanics. It is defined as the distance covered per unit of time while walking. Gait speed is often measured in meters per second (m/s) or feet per second (ft/s) and is an important indicator of overall health, functional status, and mobility.]
Natriuretic Peptide, Brain OMIT_0020024 [A PEPTIDE that is secreted by the BRAIN and the HEART ATRIA, stored mainly in cardiac ventricular MYOCARDIUM. It can cause NATRIURESIS; DIURESIS; VASODILATION; and inhibits secretion of RENIN and ALDOSTERONE. It improves heart function. It contains 32 AMINO ACIDS.]
peptide CHEBI_16670 [Amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another with formal loss of water. The term is usually applied to structures formed from alpha-amino acids, but it includes those derived from any amino carboxylic acid. X = OH, OR, NH2, NHR, etc.]
screening biomarker BMONT_0000006 [A biomarker to discriminate between healthy individuals and those in an early stage of the disease.]
stride length BMONT_0000128 [Stride length is a key parameter in the study of human gait and biomechanics. It refers to the distance covered between two successive placements of the same foot. Essentially, it is the distance traveled during one complete gait cycle, involving both the left and right foot.]
sleep quality EFO_0005272 [quantification of some aspect of sleep quality, such as number of awakenings during a sleep interval or time taken to get to sleep. Sleep quality can be evaluated either through self-reporting, observation in a sleep lab or using a sleep monitoring device]
congestive heart failure DOID_6000 [A heart disease that is characterized by any structural or functional cardiac disorder that impairs the ability of the heart to fill with or pump a sufficient amount of blood throughout the body.]
companion endpoint BMONT_0000007 [A biomarker that is essential to the efficacy and safety of a corresponding therapeutic product.]
sleep depth EFO_0005273 [self-reported assessment of how difficult an individual is to wake]
gait cycle time BMONT_0000129 [Gait cycle time is an important parameter in the study of human locomotion and biomechanics. It refers to the duration of a complete gait cycle, which encompasses all the phases of walking from one foot making contact with the ground to the same foot making contact again.]
target biomarker BMONT_0000008 [A biomarker that reports interaction of the drug with its target]
hippocampal volume EFO_0005035 [Measurement of the volume of the hippocampus]
zero-dimensional spatial region BFO_0000018
disposition BFO_0000016
blood serum specimen OBI_0100017 [A material entity which derives from blood and corresponds to blood plasma without fibrinogen or the other clotting factors.]
Prostatectomy OMIT_0012415 [Complete or partial surgical removal of the prostate. Three primary approaches are commonly employed: suprapubic - removal through an incision above the pubis and through the urinary bladder; retropubic - as for suprapubic but without entering the urinary bladder; and transurethral (TRANSURETHRAL RESECTION OF PROSTATE).]
surgical procedure MAXO_0000004 [A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery.]
Qualification of Medical Device Development Tools Guidance for Industry, Tool Developers, and Food and Drug Administration Staff BMONT_0000031 [A guidance that describes a voluntary program for the qualification of medical device development tools (MDDTs) for use in the evaluation of devices regulated by CDRH. Specifically, this guidance describes the framework for voluntary proposal and qualification of an MDDT, including definitions of applicable terms, criteria for evaluating an MDDT for a specific context of use, considerations for qualification, and the contents of a qualification package. CDRH believes that MDDTs will facilitate the development and timely evaluation of medical devices by providing a more efficient and predictable means for collecting information to support regulatory submissions and associated decision-making.]
regulatory document ICO_0000233 [A document that either prescribes actions or prescribes the permissions, obligations, restrictions, or protections relating to public or legal policy.]